> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-130/
- Published: 2017-04-09T12:00:00.000Z
- Updated: 2026-09-14T22:16:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138411

[**Antimicrobial Drugs Panel to Discuss Product Development**](https://www.fdaweb.com/antimicrobial-drugs-panel-to-discuss-product-development/) 04/07/2017  
*Federal Register* notice: FDA announces a 4/13 Antimicrobial Drugs Advisory Committee meeting on developing antibacterial drugs that treat a single species of bacteria.

[**Workshop on Kidney Transplant Rejection Drugs**](https://www.fdaweb.com/workshop-on-kidney-transplant-rejection-drugs/) 04/05/2017  
*Federal Register* Notice: FDA announces a 4/12 public workshop on new developments and scientific issues related to antibody mediated rejection in kidney transplantation.

[**FDA/Xavier University Medical Device Conference**](https://www.fdaweb.com/fda-xavier-university-medical-device-conference/) 04/05/2017  
*Federal Register* Notice: FDA co-sponsors with Xavier University a public conference entitled “FDA/Xavier University Medical Device Conference.”

[**Cedax Not Withdrawn Over Safety or Effectiveness**](https://www.fdaweb.com/cedax-not-withdrawn-over-safety-or-effectiveness/) 04/05/2017  
*Federal Register* Notice: FDA determines that Pernix Therapeutics’ antibiotic Cedax (ceftibuten dihydrate) for oral suspension, 90mg/5mL and 180mg/5mL, were not withdrawn for reasons involving safety or effectiveness.